Hemogenyx Pharmaceuticals (LON:HEMO) Shares Down 11% – Time to Sell?

Hemogenyx Pharmaceuticals Plc (LON:HEMO)’s stock price dropped 11% during trading on Thursday . The company traded as low as GBX 676 and last traded at GBX 676. Approximately 21,518 shares traded hands during mid-day trading, a decline of 12% from the average daily volume of 24,533 shares. The stock had previously closed at GBX 759.50.

Hemogenyx Pharmaceuticals Trading Down 11.0%

The firm has a fifty day simple moving average of GBX 752.05 and a two-hundred day simple moving average of GBX 828.23. The firm has a market capitalization of £45.97 million, a P/E ratio of -3.96 and a beta of 1.53. The company has a debt-to-equity ratio of 167.66, a current ratio of 1.38 and a quick ratio of 6.72.

Hemogenyx Pharmaceuticals (LON:HEMO) last issued its quarterly earnings results on Thursday, April 30th. The company reported GBX (170.60) EPS for the quarter.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.